Clinical Trial

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB14 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-05.
Trial Details
NCT Number NCT06304818
Lead Sponsor Sinocelltech Ltd.
Conditions Advanced Malignant Solid Tumours
Enrollment 515 participants
Start Date 2024-04-30
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-03-15